Syphilis Vaccines 2023

Authored by
Last reviewed
February 19, 2023
Content Overview
Syphilis vaccines continue to be developed in 2023, but no vaccine candidate has been approved.

Syphilis Vaccines 2023

The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have not approved a syphilis vaccine as of February 18, 2023.

Syphilis Vaccine Candidates 2023

July 28, 2022 - The journal Frontiers in Immunology published: Notes on syphilis vaccine development.

November 25, 2021 - Original Research: Two Potential Syphilis Vaccine Candidates Inhibit Dissemination of Treponema pallidum. These results provide novel and critical information for understanding the pathogenic mechanisms of spirochetes and the development of spirochete-specific subunit vaccines. Furthermore, these findings indicate that Tp0136 and Tp0663 are promising syphilis vaccine candidates.

Syphilis Outbreaks 2023

Population-adjusted cases of primary and secondary syphilis rose 505% between 2000 and 2020. In addition, congenital syphilis rates rose 301%, and early non-primary, non-secondary syphilis increased by 285%.

Minnesota: According to sexually transmitted diseases and HIV data from the Minnesota Department of Health, syphilis cases rose sharply in Minnesota in 2021. Syphilis cases reflected the most significant increase from 2020, with a 33% increase, to 1,457 cases reported in 2021. Fifteen cases of congenital syphilis in infants were reported in 2021. This is a 115% increase from 2020.

Missouri: The number of syphilis cases in St. Louis and St. Louis County started increasing in 2021, even as the reported number of other STDS held relatively steady. Between 2019 and 2022, the number of reported syphilis cases increased by 42% in both the city and county.